III期临床研究-话题@MedSci

#III期临床研究#

70篇内容 | 2398人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2050181, encodeId=e1f72050181fe, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, objectType=article, longId=209558, objectId=b719209558c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b719209558c2, replyNumber=0, likeNumber=84, createdTime=2021-09-26, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b719209558c2, moduleTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b719209558c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050197, encodeId=7f65205019e3a, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN, objectType=article, longId=265037, objectId=970226503ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=970226503ec6, replyNumber=0, likeNumber=158, createdTime=2022-02-25, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=970226503ec6, moduleTitle=J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=970226503ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050187, encodeId=f404205018ee3, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, objectType=article, longId=212671, objectId=87bb2126e1d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87bb2126e1d5, replyNumber=0, likeNumber=57, createdTime=2022-05-13, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87bb2126e1d5, moduleTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87bb2126e1d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050183, encodeId=15f52050183c4, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点, objectType=article, longId=210493, objectId=d849210493a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d849210493a6, replyNumber=0, likeNumber=60, createdTime=2021-09-10, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d849210493a6, moduleTitle=特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d849210493a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050193, encodeId=3ba62050193de, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST , objectType=article, longId=218140, objectId=973121814015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=973121814015, replyNumber=0, likeNumber=49, createdTime=2021-10-26, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=973121814015, moduleTitle=Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=973121814015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050180, encodeId=fd8e2050180b4, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, objectType=article, longId=204948, objectId=3cf1204948c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf1204948c8, replyNumber=0, likeNumber=92, createdTime=2021-04-15, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf1204948c8, moduleTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cf1204948c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050184, encodeId=27ad20501840f, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功, objectType=article, longId=211275, objectId=f24b2112e55c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24b2112e55c, replyNumber=0, likeNumber=84, createdTime=2022-03-12, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24b2112e55c, moduleTitle=NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24b2112e55c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050190, encodeId=bbe620501901f, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18, objectType=article, longId=216915, objectId=e8b0216915a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8b0216915a0, replyNumber=0, likeNumber=76, createdTime=2022-07-09, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8b0216915a0, moduleTitle=Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8b0216915a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050186, encodeId=504a2050186dc, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, objectType=article, longId=210359, objectId=837e210359f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=837e210359f2, replyNumber=0, likeNumber=68, createdTime=2021-08-22, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=837e210359f2, moduleTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=837e210359f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050176, encodeId=366820501e6bc, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, objectType=article, longId=201090, objectId=24af2010905f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24af2010905f, replyNumber=0, likeNumber=64, createdTime=2021-02-01, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24af2010905f, moduleTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24af2010905f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050188, encodeId=f5e120501886c, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C, objectType=article, longId=213343, objectId=818f213343eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=818f213343eb, replyNumber=0, likeNumber=66, createdTime=2022-05-28, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=818f213343eb, moduleTitle=JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=818f213343eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050178, encodeId=8a0220501e8ed, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, objectType=article, longId=202599, objectId=ad7320259999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad7320259999, replyNumber=0, likeNumber=112, createdTime=2020-12-27, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad7320259999, moduleTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad7320259999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050173, encodeId=89d020501e3a0, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=COVID-19疫苗BNT162b2进入II / III期临床研究, objectType=article, longId=198193, objectId=ccfa198193ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccfa198193ff, replyNumber=0, likeNumber=54, createdTime=2021-07-13, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccfa198193ff, moduleTitle=COVID-19疫苗BNT162b2进入II / III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccfa198193ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050179, encodeId=45d320501e94b, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, objectType=article, longId=203674, objectId=94d42036e4b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94d42036e4b2, replyNumber=0, likeNumber=76, createdTime=2021-01-15, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94d42036e4b2, moduleTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94d42036e4b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050182, encodeId=1b4d2050182b2, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, objectType=article, longId=209763, objectId=515e209e63ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=515e209e63ce, replyNumber=0, likeNumber=141, createdTime=2021-12-22, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=515e209e63ce, moduleTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=515e209e63ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050174, encodeId=c1fd20501e4e4, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, objectType=article, longId=199310, objectId=a5e8199310d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5e8199310d0, replyNumber=0, likeNumber=45, createdTime=2021-06-17, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5e8199310d0, moduleTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5e8199310d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050175, encodeId=177f20501e5c0, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败, objectType=article, longId=200768, objectId=614b200e686d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=614b200e686d, replyNumber=0, likeNumber=61, createdTime=2021-06-07, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614b200e686d, moduleTitle=Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=614b200e686d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050172, encodeId=f1c120501e224, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究, objectType=article, longId=197608, objectId=a82f19e608e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a82f19e608e8, replyNumber=0, likeNumber=63, createdTime=2020-10-04, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a82f19e608e8, moduleTitle=靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a82f19e608e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050177, encodeId=e4d420501e7cf, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, objectType=article, longId=201382, objectId=2172201382b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2172201382b6, replyNumber=0, likeNumber=65, createdTime=2021-01-28, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2172201382b6, moduleTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2172201382b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050168, encodeId=489e205016899, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究, objectType=article, longId=182069, objectId=fe64182069a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe64182069a8, replyNumber=0, likeNumber=68, createdTime=2020-05-30, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe64182069a8, moduleTitle=维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe64182069a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期临床研究

2020-05-29

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功

2021-09-26

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN

2022-02-25

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1

2022-05-13

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点

2021-09-10

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST

2021-10-26

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究

2021-04-15

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功

2022-03-12

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18

2022-07-09

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！

2021-08-22

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期

2021-02-01

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C

2022-05-28

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

拜耳Finerenone FIDELIO-DKD III期临床研究结果公布

2020-12-27

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

COVID-19疫苗BNT162b2进入II / III期临床研究

2021-07-13

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果

2021-01-15

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解

2021-12-22

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期

2021-06-17

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败

2021-06-07

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究

2020-10-04

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著

2021-01-28

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究

2020-05-30

科室
- - 订阅+
  - 更多科室
工具
服务